Biopharma Manufacturing Disruptions from COVID-19

The rapid spread of COVID-19 has created a new business reality. This is especially true for companies involved with pharmaceutical manufacturing (e.g clinical and commercial supply), delivering vital products to the clinical stage has become substantially harder. Many employees are required to work from home, supply chains are undependable, and clinical research partners may be pulled away from a trial to other priorities. At the same time, development timelines have to be met, or in some cases are now compressed. These challenges can seem overwhelming but there is a way to adapt and thrive.

To help you adjust and plan for the future of your CMC program, we will be joined by Dr. Kevin Bittorf, an expert in pharmaceutical manufacturing with 20-plus years of experience. Join our webinar, to learn:

• The ways pharmaceuticals manufacturing is being disrupted

• A framework for assessing risks to your manufacturing program

• Priorities for re-planning activities across the supply chain (starting materials, drug substance, regulatory, etc.)

• Mindset shifts to take advantage of this time to strengthen your manufacturing efforts